Cathepsin D protects human neuroblastoma cells from doxorubicin-induced cell death

Carcinogenesis

Volumn 29, Issue 10, 2008, Pages 1869-1877

  Sagulenko, Vitalia ^a   Muth, Daniel ^a   Sagulenko, Evgeny ^a   Paffhausen, Tobias ^a   Schwab, Manfred ^a   Westermann, Frank ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN D; DOXORUBICIN; LUCIFERASE; MESSENGER RNA; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MYCN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOLECULAR CLONING; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RNA INTERFERENCE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CATHEPSIN D; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME PRECURSORS; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEINS; SIGNAL TRANSDUCTION;

EID: 53349091482     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn147     Document Type: Article

References (44)

1. Schwab,M. et al. (2003) Neuroblastoma: Biology and molecular and chromosomal pathology. Lancet Oncol., 4, 472-480.
2. Bordow,S.B. et al. (1998) Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. J. Clin. Oncol., 16, 3286-3294.
3. Haber,M. et al. (2006) Association of high-level MRP1 expression with poor clinical outcome in a large prospective study of primary neuroblastoma. J. Clin. Oncol., 24, 1546-1553.
4. Fulda,S. et al. (2003) Apoptosis pathways in neuroblastoma therapy. Cancer Lett, 197, 131-135.
5. Hurlin,P.J. (2005) N-Myc functions in transcription and development. Birth Defects Res. C Embryo Today, 75, 340-352.
6. Lutz,W. et al. (1996) Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into-G-phase early after mitogenic stimulation of quiescent cells. Oncogene, 43 803-812.
7. Weiss,W.A. et al. (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J., 16, 2985-2995.
8. Schweigerer,L. et al. (1990) Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: Evidence for induction of autocrine growth factor activity. Cancer Res., 50 4411-4416.
9. Fulda,S. et al. (1999) MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene, 18, 1479-1486.
10. Lutz,W. et al. (1998) MycN and IFNgamma cooperate in apoptosis of human neuroblastoma cells. Oncogene, 17, 339-346.
11. Paffhausen,T. et al. (2007) Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett., 250, 17-24.
12. Gewirtz,D.A. (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 57, 727-741.
13. Tokarska-Schlattner,M. et al. (2006) New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. J. Mol. Cell. Cardiol., 41, 389-405.
14. Rebbaa,A. et al. (2003) Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene, 22, 2805-2811.
15. Rebbaa,A. et al. (2001) Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis. Mol. Med., 7, 393-400.
16. Hopkins-Donaldson,S. et al. (2002) Doxorubicin-induced death in neuroblastoma does not involve death receptors in S-type cells and is caspase, independent in N-type cells. Oncogene, 21, 6132-6137.
17. Wittke,I. et al. (2001) DAP-5 is involved in MycN/IFNgamma-induced apoptosis in human neuroblastoma cells. Cancer Lett., 162, 237-243.
18. Wiedemeyer,R. et al. (2003) Ataxin-2 promotes apoptosis of human neuroblastoma cells. Oncogene, 22, 401-411.
19. Henrich,K.O. et al. (2006) Reduced expression of CAMTA1 correlates with adverse outcome in neuroblastoma patients. Clin. Cancer Res., 12, 131-138.
20. Westermann,F. et al. (2007) High Skp2 expression characterizes high-risk neuroblastomas independent of MYCN status. Clin. Cancer Res., 13, 4695-4703.
21. Kimchi,A. (2003) Antisense libraries to isolate tumor suppressor genes. Methods Mol. Biol., 222, 399-412.
22. Roninson,I.B. et al. (2003) GSE in the characterization and identification of tumor suppressor genes. Methods Mol. Biol., 222, 413-436.
23. Kissil,J.L. et al. (1995) Isolation of DAP3, a novel mediator of interferon-gamma-induced cell death. J. Biol. Chem., 270, 27932-27936.
24. Deiss,L.P. et al. (1996) Cathepsin D protease mediates programmed cell death induced by interferon-ganirna, Fas/APO-1 and TNF-alpha. EMBO J., 15, 3861-3870.
25. Liaudet-Coopman,E. et al. (2006) Cathepsin D: Newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett., 237, 167-179.
26. Basu,A. et al. (2006) Posttranslational modifications of Bcl2 family members - a potential therapeutic target for human malignancy. Front. Biosci., 11, 1508-1521.
27. Leto,G. et al. (2004) Cathepsin D expression levels in nongynecological solid tumors: Clinical and therapeutic implications. Clin. Exp. Metastasis, 21, 91-106.
28. Vetvicka,V. et al. (2002) Procathepsin D in breast cancer: What do we know? Effects of ribozymes and other inhibitors. Cancer Gene Ther. 9, 854-863.
29. Stoka,V. et al. (2007) Lysosomal cysteine cathepsins: Signaling pathways in apoptosis. Biol. Chem., 388, 555-560.
30. Castino,R. et al. (2002) Lysosomal proteases as potential targets for the induction of apoptotic cell death in human neuroblastomas. Int. J. Cancer, 97, 775-779.
31. Tweddle,D.A. et al. (2003) The p53 pathway and its inactivation in neuroblastoma. Cancer Lett., 197, 93-98.
32. Deng,X. et al. (2006) Bcl2's flexible loop domain regulates p53 binding and survival. Mol. Cell. Biol., 26, 4421-4434.
33. Opel,D. et al. (2007) Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res., 67, 735-745.
34. Koike,M. et al. (2000) Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J. Neurosci., 20, 6898-6906.
35. Shacka,J.J. et al. (2007) Cathepsin D deficiency induces persistent neuro-degeneration in the absence of Bax-dependent apoptosis. J. Neurosci., 27, 2081-2090.
36. Walls,K.C. et al. (2007) Altered regulation of phosphatidylinositol 3-kinase signaling in cathepsin D-deficient brain. Autophagy, 3, 222-229.
37. Emran,M.A. et al. (2002) Doxorubicin resistant neuroblastoma cells secrete factors that activate AKT and attenuate cytotoxicity in drug-sensitive cells. Cancer Lett., 182, 53-59.
38. Mirkin,B.L. et al. (2005) Identification of midkine as a mediator for intercellular transfer of drug resistance. Oncogene, 24, 4965-4974.
39. Fukuda,M.E. et al. (2005) Cathepsin D is a potential serum marker for poor prognosis in glioma patients. Cancer Res., 65, 5190-5194.
40. Henry,J.A. et al. (1990) Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer, 65, 265-271.
41. Leto,G. et al. (1992) Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res., 12, 235-240.
42. Rochefort,H. (1992) Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol., 31, 125-130.
43. Magro,G. et al. (2000) Cathepsin D is a marker of ganglion cell differentiation in the developing and neoplastic human peripheral sympathetic nervous tissues. Virchows Arch., 437, 406-412.
44. Parham,D. et al. (1985) Cellular distribution of cathepsin D in childhood tumors. Arch. Pathol. Lab. Med., 109, 250-255.